NASDAQ$ETON
Eton Pharmaceuticals Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Eton Pharmaceuticals reported a 50% increase in revenue and a net loss reduction compared to the prior year period.
Eton Pharmaceuticals reported a strong start to 2024, marked by record product sales, a 50% revenue increase compared to Q1 2023, and the acquisition of PKU GOLIKE. The company also launched Nitisinone and submitted an NDA for ET-400.
- Q1 2024 revenue reached $8.0 million, a 50% increase year-over-year.
- The company achieved its 13th consecutive quarter of sequential product sales growth.
- Eton acquired U.S. rights to PKU GOLIKE and launched Nitisinone, expanding its metabolic portfolio.
- An NDA was submitted to the FDA for ET-400, with potential approval expected in early 2025.
Headline financials
Revenue & EPS history
Eton · Revenue · Quarterly
$7.97M
Revenue by segment
Eton · $24.3M total across 1 segment · Q1 2026
- Product Sales and Royalties$24.3M—100.0%
Forward guidance
Eton Pharmaceuticals anticipates continued sequential quarter-over-quarter growth of product sales throughout 2024 and beyond. With the addition of PKU GOLIKE and Nitisinone, the company is positioned for a strong 2024 and gears up for potential launch of ET-400 in early 2025
Tailwinds
- Continued sequential quarter-over-quarter growth of product sales is expected throughout 2024 and beyond.
- The company anticipates continued sales growth to result in positive operating cash flow throughout the remainder of 2024.
- Strong growth expected from existing products.
- The additions of PKU GOLIKE and Nitisinone will strenghten the portfolio.
- Potential launch of ET-400 in early 2025
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2024
+0.6%
Avg return
Earnings day
+2.3%
Avg return
5 days after
+1.3%
Avg return
30 days after
48%
15 / 31 earnings
Positive
+36.0%
Q2 2023
Best reaction
-14.1%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +7.5% | -4.7% | — | |
| Q1 2026 | -3.0% | +6.7% | +2.4% | |
| Q3 2025 | -11.4% | -8.8% | -15.0% | |
| Q2 2025 | +12.5% | +12.2% | +15.8% | |
| Q1 2025 | +0.4% | +14.6% | -16.2% | |
| Q4 2024 | -4.0% | -7.0% | -6.2% | |
| Q3 2024 | +9.2% | +3.2% | +25.2% | |
| Q2 2024 | +6.6% | +8.0% | +31.5% | |
| Q1 2024 | -7.8% | -2.4% | -3.0% | |
| Q4 2023 | -14.1% | -21.0% | -23.7% | |
| Q3 2023 | -13.7% | -16.6% | -19.1% | |
| Q2 2023 | +36.0% | +79.5% | +83.7% | |
| Q1 2023 | +2.8% | +2.6% | +10.3% | |
| Q4 2022 | +2.6% | +7.1% | -7.4% | |
| Q3 2022 | +18.5% | +20.9% | +22.8% | |
| Q2 2022 | -1.0% | -19.4% | -22.8% | |
| Q1 2022 | +1.3% | +6.5% | -4.9% | |
| Q4 2021 | +6.1% | +8.7% | -1.5% | |
| Q3 2021 | -3.4% | -9.2% | -20.7% | |
| Q2 2021 | -5.0% | -0.2% | +12.7% | |
| Q1 2021 | +5.2% | +7.5% | -13.4% | |
| Q4 2020 | -0.7% | -1.1% | +5.9% | |
| Q3 2020 | -1.5% | +2.9% | +19.9% | |
| Q2 2020 | -2.2% | +4.4% | +12.4% | |
| Q1 2020 | -9.2% | -10.3% | -1.1% | |
| Q4 2019 | -8.4% | -21.9% | -39.8% | |
| Q3 2019 | +1.9% | +2.3% | +9.2% | |
| Q2 2019 | +1.6% | -1.8% | -14.2% | |
| Q1 2019 | +3.2% | +12.2% | +5.9% | |
| Q4 2018 | -2.3% | +2.6% | -5.8% | |
| Q3 2018 | -8.1% | -4.8% | -3.2% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro